Critical Limb Ischemia (Cardiovascular) – Drugs In Development, 2021

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Critical Limb Ischemia – Drugs In Development, 2021, provides an overview of the Critical Limb Ischemia (Cardiovascular) pipeline landscape.Critical limb ischemia (CLI) is the most severe form of peripheral arterial disease (PAD). It is caused by chronic inflammatory processes associated with atherosclerosis that result in reduced blood flow to the legs, feet and hands. Symptoms include pain or numbness in feet or toes, sores, skin infections will not heal. Treatment goals for CLI include reducing the number of cardiovascular risk factors (such as quitting smoking and reduction of cholesterol), relieving pain, healing ulcers, preventing major amputation, improving quality of life and increasing survival.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Critical Limb Ischemia – Drugs In Development, 2021, provides comprehensive information on the therapeutics under development for Critical Limb Ischemia (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.The Critical Limb Ischemia (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Critical Limb Ischemia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 2, 13, 3, 2, 10 and 1 respectively. Similarly, the Universities portfolio in Phase II and Preclinical stages comprises 1 and 1 molecules, respectively.

Critical Limb Ischemia (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

– The pipeline guide provides a snapshot of the global therapeutic landscape of Critical Limb Ischemia (Cardiovascular).

– The pipeline guide reviews pipeline therapeutics for Critical Limb Ischemia (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.

– The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

– The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

– The pipeline guide reviews key companies involved in Critical Limb Ischemia (Cardiovascular) therapeutics and enlists all their major and minor projects.

– The pipeline guide evaluates Critical Limb Ischemia (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

– The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

– The pipeline guide reviews latest news related to pipeline therapeutics for Critical Limb Ischemia (Cardiovascular)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Critical Limb Ischemia (Cardiovascular).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Critical Limb Ischemia (Cardiovascular) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Companies mentioned

Ambulero Inc

Anaeropharma Science Inc

Antidote Therapeutics Inc

Athersys Inc

Caladrius Biosciences Inc

Constant Therapeutics LLC

Cynata Therapeutics Ltd

GPCR Therapeutics Inc

Gurus BioPharm

Helixmith Co Ltd

Hemostemix Inc

ID Pharma Co Ltd

Ixaka Ltd

Juventas Therapeutics Inc

Libella Gene Therapeutics

LifeCells LLC

New B Innovation Ltd

Pharmicell Co Ltd

Pluristem Therapeutics Inc

ReNeuron Group Plc

Reven Pharmaceuticals Inc

S.Biomedics Co Ltd

Taiwan Bio Therapeutics Co Ltd

Theratome Bio Inc

U.S. Stem Cell Inc

VESSL Therapeutics Ltd

Table of Contents

Table of Contents

Introduction

Critical Limb Ischemia - Overview

Critical Limb Ischemia - Therapeutics Development

Critical Limb Ischemia - Therapeutics Assessment

Critical Limb Ischemia - Companies Involved in Therapeutics Development

Critical Limb Ischemia - Drug Profiles

Critical Limb Ischemia - Dormant Projects

Critical Limb Ischemia - Discontinued Products

Critical Limb Ischemia - Product Development Milestonesh

Appendix

List of Tables

List of Tables

Number of Products under Development for Critical Limb Ischemia, 2021

Number of Products under Development by Companies, 2021

Number of Products under Development by Universities/Institutes, 2021

Products under Development by Companies, 2021

Products under Development by Universities/Institutes, 2021

Number of Products by Stage and Target, 2021

Number of Products by Stage and Mechanism of Action, 2021

Number of Products by Stage and Route of Administration, 2021

Number of Products by Stage and Molecule Type, 2021

Critical Limb Ischemia – Pipeline by Ambulero Inc, 2021

Critical Limb Ischemia – Pipeline by Anaeropharma Science Inc, 2021

Critical Limb Ischemia – Pipeline by Antidote Therapeutics Inc, 2021

Critical Limb Ischemia – Pipeline by Athersys Inc, 2021

Critical Limb Ischemia – Pipeline by Caladrius Biosciences Inc, 2021

Critical Limb Ischemia – Pipeline by Constant Therapeutics LLC, 2021

Critical Limb Ischemia – Pipeline by Cynata Therapeutics Ltd, 2021

Critical Limb Ischemia – Pipeline by GPCR Therapeutics Inc, 2021

Critical Limb Ischemia – Pipeline by Gurus BioPharm, 2021

Critical Limb Ischemia – Pipeline by Helixmith Co Ltd, 2021

Critical Limb Ischemia – Pipeline by Hemostemix Inc, 2021

Critical Limb Ischemia – Pipeline by ID Pharma Co Ltd, 2021

Critical Limb Ischemia – Pipeline by Ixaka Ltd, 2021

Critical Limb Ischemia – Pipeline by Juventas Therapeutics Inc, 2021

Critical Limb Ischemia – Pipeline by Libella Gene Therapeutics, 2021

Critical Limb Ischemia – Pipeline by LifeCells LLC, 2021

Critical Limb Ischemia – Pipeline by New B Innovation Ltd, 2021

Critical Limb Ischemia – Dormant Projects, 2021

Critical Limb Ischemia – Discontinued Products, 2021

List of Figures

List of Figures

Number of Products under Development for Critical Limb Ischemia, 2021

Number of Products under Development by Companies, 2021

Number of Products under Development by Universities/Institutes, 2021

Number of Products by Targets, 2021

Number of Products by Stage and Targets, 2021

Number of Products by Mechanism of Actions, 2021

Number of Products by Stage and Mechanism of Actions, 2021

Number of Products by Top 10 Routes of Administration, 2021

Number of Products by Stage and Top 10 Routes of Administration, 2021

Number of Products by Molecule Types, 2021

Number of Products by Stage and Molecule Types, 2021

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports